AU2002210385A1 - Furazanyl-triazole derivates for the treatment of diseases - Google Patents
Furazanyl-triazole derivates for the treatment of diseasesInfo
- Publication number
- AU2002210385A1 AU2002210385A1 AU2002210385A AU1038502A AU2002210385A1 AU 2002210385 A1 AU2002210385 A1 AU 2002210385A1 AU 2002210385 A AU2002210385 A AU 2002210385A AU 1038502 A AU1038502 A AU 1038502A AU 2002210385 A1 AU2002210385 A1 AU 2002210385A1
- Authority
- AU
- Australia
- Prior art keywords
- furazanyl
- diseases
- treatment
- triazole derivates
- derivates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200001537 | 2000-10-16 | ||
| DKPA200001537 | 2000-10-16 | ||
| US24240900P | 2000-10-20 | 2000-10-20 | |
| US60242409 | 2000-10-20 | ||
| PCT/DK2001/000676 WO2002032896A1 (en) | 2000-10-16 | 2001-10-12 | Furazanyl-triazole derivates for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002210385A1 true AU2002210385A1 (en) | 2002-04-29 |
Family
ID=26068893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002210385A Abandoned AU2002210385A1 (en) | 2000-10-16 | 2001-10-12 | Furazanyl-triazole derivates for the treatment of diseases |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002210385A1 (en) |
| WO (1) | WO2002032896A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003027068A2 (en) * | 2001-09-24 | 2003-04-03 | Elan Pharmaceuticals, Inc. | Substituted amines for the treatment of neurological disorders |
| JP4881725B2 (en) * | 2003-04-09 | 2012-02-22 | エクセリクシス， インク． | TIE-2 modulator and usage |
| JP2007512230A (en) * | 2003-08-20 | 2007-05-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | (4-Amino-1,2,5-oxadiazol-4-yl) -heteroaromatic compounds useful as protein kinase inhibitors |
| US20070203098A1 (en) * | 2004-04-06 | 2007-08-30 | Semafore Pharmaceuticals, Inc. | Pten Inhibitors |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| ES2624791T3 (en) * | 2006-11-21 | 2017-07-17 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| WO2009009768A2 (en) * | 2007-07-12 | 2009-01-15 | Acumen Pharmaceuticals, Inc. | METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS |
| US8962677B2 (en) | 2007-07-12 | 2015-02-24 | Acumen Pharmaceuticals, Inc. | Methods of restoring cognitive ability using non-peptidic compounds |
| US9006283B2 (en) | 2007-07-12 | 2015-04-14 | Acumen Pharmaceuticals, Inc. | Methods of modifying amyloid β oligomers using non-peptidic compounds |
| WO2009079566A2 (en) | 2007-12-18 | 2009-06-25 | Acumen Pharmaceuticals, Inc. | Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production |
| AU2009255973B2 (en) | 2008-06-06 | 2013-08-15 | Children's Medical Center Corporation | Promoting axon regeneration in the adult CNS through control of protein translation |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4920397A (en) * | 1996-10-11 | 1998-05-11 | Chiron Corporation | Purine inhibitors of glycogen synthase kinase 3 (gsk3) |
| ATE274510T1 (en) * | 1998-06-19 | 2004-09-15 | Chiron Corp | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS |
-
2001
- 2001-10-12 WO PCT/DK2001/000676 patent/WO2002032896A1/en active Application Filing
- 2001-10-12 AU AU2002210385A patent/AU2002210385A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002032896A1 (en) | 2002-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03002814A (en) | Morpholin-acetamide derivatives for the treatment of inflammatory diseases. | |
| AU2002332430A1 (en) | Methods of treating neuropilin-mediated diseases | |
| AU2002223827A1 (en) | Well treatment | |
| AU2002348135A1 (en) | Methods for the treatment of addiction | |
| IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
| AU2002222853A1 (en) | Therapeutic compounds | |
| AU2002257936A1 (en) | Methods of well treatment | |
| AU2002210385A1 (en) | Furazanyl-triazole derivates for the treatment of diseases | |
| AU2002334870B8 (en) | Combinations for the treatment of immunoinflammatory disorders | |
| AU7622000A (en) | Compounds for the treatment of viral-mediated diseases | |
| AU2001260834A1 (en) | The treatment of herpes | |
| AU2002353739A1 (en) | Therapeutic compounds | |
| AU2002319286A1 (en) | Skin treatment | |
| AU2002227895A1 (en) | Sulphonamides for the treatment of central nervous system diseases | |
| AU2001267404A1 (en) | Novel compounds for the treatment of inflammatory and cardiovascular diseases | |
| AU2002258798A1 (en) | Methods for the treatment of hepatic disorders | |
| AU2002359635A1 (en) | Use of polycyclic phenolic compounds for the treatment of opthalmic diseases | |
| AU2002304883A1 (en) | Device for the treatment of tumours | |
| AU1405001A (en) | Treatment of diseases | |
| AU2001262520A1 (en) | Combined preparation for the treatment of neoplasic diseases | |
| AU2001253560A1 (en) | Methods of treatment | |
| AU2002247836A1 (en) | Mycobacterrial estracts for treating autoimmune diseases | |
| AU2002357964A1 (en) | Use of coagulant-active antitrhombin iii for the therapy of angiogenesis-dependent diseases | |
| AU2000272704A1 (en) | Use of compounds for the treatment of obesity | |
| AU2001274446A1 (en) | Vip-related peptides for the treatment of skin disorders |